本帖最后由 老马 于 2012-1-13 21:20 编辑
0 l! z1 s/ w& \( K" K% [
& }3 _) b0 g3 q4 y7 U爱必妥和阿瓦斯丁的比较 k* n- L4 W3 I) |2 |
: H( I2 I! e7 ehttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
# w* @9 [- p- }7 K9 {' L
6 [6 i9 U4 H2 z m- `
7 F! {# [4 w& e- v! x& ]- U, d
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/: ] m, L" H, J) ?: p
==================================================0 M, a5 s G/ p, ~1 O
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)! q# o7 Q t4 M7 ]
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
8 v$ L! H: Z6 W1 E: [1 k0 D; {2 ]Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.+ `5 f' [ A& n! R3 s6 d% A0 D
|
显身卡
* a/ C M6 [4 {0 V0 A( d+ w, l
